OncoBay Clinical and Clinscience Partner to Expand Immuno-oncology Research Globally
OncoBay Clinical and Clinscience Partner to Expand Immuno-oncology Research Globally
TAMPA, FL – January 9, 2023
OncoBay Clinical, an oncology-focused boutique clinical research organization (CRO) initially funded by Moffitt Cancer Center, has partnered with Clinscience, a global CRO based in Warsaw, Poland. The investment gives NEUCA Group, Clinscience’s parent company, a majority stake in OncoBay. The partnership immediately unites OncoBay’s unrivaled scientific expertise and deep US clinical network with NEUCA Group’s revolutionary technology services and extensive European presence. The partnership provides a significant global footprint with physical offices in United States, Poland, Germany, Spain, Italy, and India. The new global partnership will work to advance immuno-oncology research for a global portfolio of clients.
OncoBay was formed by Moffitt in 2019 to offer streamlined, custom-curated services for biopharmaceutical and biotechnology companies conducting research in the immuno-oncology space. Since its inception, OncoBay has grown to provide services for over 60 clients, with many clinical trials being conducted in partnership with Clinscience; this new partnership builds upon a 2 year relationship between the companies.
Clinscience is a global CRO with a focus on patient centricity and data centralization that has provided its service to over 150 biotechnology clients worldwide. As part of the listed parent company, NEUCA Group, since 2015, Clinscience is known industry-wide for its data-driven procedures and approach, and for their ability to improve patient experience and retention by use of its digital-health technologies.
“This innovation collaboration gives us an exciting opportunity to build upon our clinical expertise, innovative analytics, and data-assessment tools to impact immuno-oncology research globally. The goal is to transform and accelerate discoveries to reach patients more quickly,” said Krystyna Kowalczyk, OncoBay CEO and co-founder.
“The unbound dedication to immuno-oncology, tailored solutions, and use of technology and data consistency are elements that tied our organizations right from the beginning. Our combined powers, supercharged by complementing competencies, proprietary technologies, and streamlined organizational structure, set the stage for a full-scale global alternative in the clinical research market,” said Tomek Dabrowski, Executive Chairman of Clinscience. “It allows us to further expand our abilities in cancer research providing our clients with comprehensive support in their pursuit to develop innovative cancer treatments.”
“Moffitt made an investment 3 years ago when it launched OncoBay, and in that short period of time we have taken this concept to a global entity with an international research footprint,” said James Mulé, iPhD, associate center director of Translational Science at Moffitt and OncoBay advisor. “This new partnership with Clinscience will allow us to continue to provide tailored immuno-oncology on a much larger scale.”
Kowalczyk will remain CEO of the combined OncoBay and Clinscience operation. She and Dannelle Palmer, OncoBay’s Chief Operating Officer, will also join NEUCA Group’s leadership team.
About OncoBay Clinical
OncoBay Clinical is a boutique CRO specializing in immuno-oncology (IO)/cell therapy, offering full-service custom-curated CRO solutions for global pharmaceutical and biotechnology companies looking to advance their immuno-oncology product or device. Built on years of IO and cell-therapy expertise, a streamlined technology framework, a highly trained site network, and a dedicated team of experienced professionals, OncoBay embeds scientific expertise and operational excellence into all of its projects.
About Clinscience
Clinscience is a global CRO company offering intelligent (end-to-end) CRO services, ie, from protocol creation to final study report development. More than 150 clients of Biotechnology companies in Europe and USA trust the Clinscience brand. The company has offices in Poland, Spain, Italy, Germany, and USA and provides its services in 6 European countries.
About Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 53 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 7,800 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488) or visit MOFFITT.org.
About NEUCA GROUP
The NEUCA Group has been operating in the area of healthcare for 30 years, synergistically combining the needs of pharmacists, manufacturers, and patients. It is the market leader in the wholesale distribution of pharmaceuticals in Poland. The key partners for the NEUCA Group are independent pharmacists, whom the Group supports in their daily operation of pharmacies, providing tools to build competitiveness and profitability. The NEUCA Group cares for the health of its patients by developing a network of medical clinics. It is an expert in the clinical research segment, executes ambitious telemedicine projects, and successfully operates in e commerce. It is also an experienced producer of medicines and pharmacy preparations. Since 2004, NEUCA has been a publicly company listed on the Warsaw Stock Exchange, regularly improving its financial results.
